Allos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010

WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that the Company will report its financial results for the third quarter ended September 30, 2010 on Thursday, November 4, 2010, after the financial markets close. Following the release of the financial results, Allos management will provide a corporate update and review of the third quarter 2010 results via audio webcast conference call on Thursday, November 4, 2010, at 4:30 p.m. Eastern Time (ET).

To access the live audio webcast or the subsequent archived recording, visit the “Investors - Presentations and Events” section of the Company’s website at www.allos.com. Alternatively, callers may participate in the conference call by dialing 1-877-941-2928 (U.S.) or +480-629-9725 (Canada and international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through November 18, 2010. To access the replay, callers should dial 1-800-406-7325 (domestic) or 303-590-3030 (international) and use passcode 4375395#.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other hematologic malignancies and solid tumors. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit www.allos.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of these presentations, except as required by law.



CONTACT:

Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.